Camurus Stock Surges on Record Sales and Reaffirmed 2026 Guidance

Shares of Camurus AB (CAMX) surged on Monday after the Swedish biopharmaceutical company reported record quarterly product sales and a sharp increase in royalty revenue, while reaffirming its full-year financial guidance for 2026.

Record Sales and Reaffirmed Outlook

According to its second-quarter and first-half 2026 interim report, Camurus' total revenue climbed 4% year-over-year to SEK 702 million. This was driven by an all-time high in product sales of SEK 528 million and a 42% jump in royalty revenue to SEK 127 million, reflecting strong commercial performance of its opioid dependence therapies.

While operating profit held steady at SEK 293 million and net profit dipped slightly to SEK 241 million, investors focused on the company's reaffirmed full-year guidance. Camurus continues to project 2026 revenue between SEK 2.6 billion and SEK 2.9 billion, with operating profit expected between SEK 900 million and SEK 1.2 billion. This confirmation provided a key confidence signal after what the source described as a turbulent prior quarter.

Pipeline Milestones Support Growth Narrative

Beyond the strong financial results, the company also reported significant progress across its development pipeline, providing further support for its growth prospects. Key updates include:

Ad

• CAM2029 (acromegaly): The company has addressed outstanding comments from the U.S. Food and Drug Administration (FDA) related to a Complete Response Letter and expects a regulatory update shortly.
• SORENTO Study: The pivotal Phase 3 trial for its treatment of gastroenteropancreatic neuroendocrine tumors remains on track for a primary analysis readout in Q4 2026.
• CAM2056 (semaglutide): Preparations are underway for a Phase 2b trial of its monthly semaglutide candidate, a program attracting attention in the competitive weight-loss therapy market.

Market Reaction

In response to the report, Camurus stock climbed 14.3% to SEK 601.5 in Monday trading. The move was company-specific, as industry peers in the Swedish pharmaceutical sector were trading flat to lower, underscoring that the rally was not driven by a broader market or sector trend.

The strong results and reaffirmed outlook appeared to alleviate investor concerns over execution risk. The positive report helped close a perceived valuation gap between the stock's recent trading range and the more bullish price targets maintained by market analysts.